PETER BLAISDELL | MEMBER SCIENTIFIC ADVISORY BOARD | IMMUNOTHERAPY COMPANY
Peter Blaisdell, Ph.D., is currently a member of the scientific advisory committee for a Southern California based immuno-therapy company as well as being a member of the screening committee for the SoCalBio Investor Conference. Previously, he was an Executive Director, Global Study Management, at Amgen. While at Amgen from 1998 – 2014, he supported clinical research programs in infectious disease and nephrology. He has since led global teams in conducting pulmonary, cardiovascular and nephrology outcomes trials, successfully executing international phase 2 and 3 trials in support of filings as well as phase 4 trials providing post-marketing support for a variety of therapies. Before joining Amgen, Dr. Blaisdell was a Senior Project Manager at Quintiles in their Mountain View, California office where he coordinated cross-functional teams in support of phase 2 – 4 trials for biotech and large pharma sponsors across a diverse range of therapeutic areas. He has contributed to cross-industry initiatives to expand the demographic diversity of trial enrollment and foster improved outreach to patient advocacy groups. Dr Blaisdell has authored both basic research publications and business management articles focusing on the bio/pharma industry and has taught graduate business classes on research management in MBA programs. He holds a Ph.D. in Biochemistry from the University of Minnesota where he also conducted post-doctoral research in microbiology. His B.S. is from the Univesity of Michigan.
ROBERT BERLINER | FOUNDER | BERLINER & ASSOCIATES
Robert Berliner is the founder of Berliner & Associates, a full service intellectual property firm specializing in patent, trademark and copyright prosecution, licensing and litigation. The firm has patent expertise in many fields and routinely assists with University patent programs and technology transfer. The firm also has close familiarity with the special needs of early stage companies. With a network of top ranked associate firms in more than 20 countries, Berliner & Associates can meet all your U. S. and international intellectual property needs.
GEORGE COLINDRES | SENIOR COUNSEL | PERKINS COIE
George Colindres is senior counsel with the Corporate practice and Emerging Companies & Venture Capital practice in the firm’s Los Angeles and San Diego offices.
He acts as outside general counsel for clients in a diverse array of industries, including social networking, e-commerce, online advertising, online gaming, software, hardware, telecommunications, medical devices, biotechnology, pharmaceuticals and real estate. His work for these clients includes:
- Corporate governance, including entity formation and capital structuring and equity incentive plan matters
- Commercial and licensing agreements, including drafting and negotiating confidentiality/nondisclosure, clinical trial, distribution, development, manufacturing, VAR and OEM 2nd co-marketing agreements, terms of service/use and privacy policies
- Employment and compensation matters
- Preferred Stock and other equity financings
- Convertible promissory note (bridge) financings
- Venture debt financings and other secured transactions
- M&A transactions
- Public offerings
George also represents venture capital firms, private equity firms, real estate funds, strategic investors, angels and angel groups and other investors in connection with fund formation, governance matters, making investments and M&A transactions.
William Dolphin, PhD, is a private investor and entrepreneur with a history of success running international private and publicly listed companies. His experience covers a range of industry sectors including bio-technology, pharmaceuticals, medical devices and health IT. He has significant M&A experience including 2 acquisitions and 3 sales, 2 of which were acquired by publicly traded companies. Additionally, William has served as managing- and non-executive director on the Boards of numerous public and private companies in the US, UK, Italy, Hong Kong, Australia and New Zealand. Dr. Dolphin holds a PhD in BioPhysics from Boston University where he subsequently served as Professor in the Department of Biomedical Engineering.
STEVE GOLDMAN | PRESIDENT | WORLD WIDE MIND
Steve Goldman is President of World Wide Mind Advertising: Creating Brand Smiles™ Through Analytics Powered Creativity. Steve’s a serial entrepreneur, co-founder of ACE Metrix™ – the industry standard in creative effectiveness analytics – and a writer, speaker, teacher on leadership, marketing and startups. Steve’s currently incubating a SaaS in BI. Steve’s passionate about social causes including childhood hunger, the obesity pandemic, and the spinal cord injured community. He’s also a member of The Keiretsu Forum and SoCalBio, mentoring and investing in socially conscious startups and early stage companies.
ZAFIRIOS GOURGOULIATOS | ENTREPRENEUR | LEILUX INC
Zafirios Gourgouliatos, Ph.D. is an entrepreneur with extensive experience in medical device development and regulatory strategy in a start-up environment.
As a senior scientist with start-up Cogent Light Technologies, in the early 90ies, he developed high power single fiber illumination systems for endoscopy and surgical headlights. The product lines were acquired by Welch Allyn and one product line is still being sold today.
Afterward, he co-founded LMD, and designed products for ultraviolet light treatment for psoriasis and vitiligo. The company was started in his garage. The product lines were sold to a phototherapy device company.
Zafirios holds a Ph.D. in Biomedical Engineering from the University of Texas at Austin and is a Fulbright Scholarship recipient. His B.S. is in Electrical and Electronic Engineering.
DAVE D HOOD | PRESIDENT & CEO | DH3 & ASSOCIATES
Dave D Hood is President and CEO of DH3 & Associates, a consulting company focusing on performing technology assessments and developing strategies for product development and business development. Emphasizing the pursuit and capture of non-dilutive funding coupled with institutional and strategic investors. Expertise and experience with intrapreneurship, entrepreneurship, product development, project/program management, business management and business development. Helping companies work with the government – particularly the military/DOD. Highly regarded as a subject matter expert. Frequent invited speaker at various academic and industry venues domestic and international.
WENDIE JOHNSTON | LAB DIRECTOR | PASADENA BIOSCIENCE COLLABORATIVE
Wendie Johnston, Ph.D. (UCLA, 1968) designed and was the first Director of the Biological Technology Program at Pasadena City College. She is currently Lab Director at the Pasadena Bioscience Collaborative wet lab incubation and training facility and is on the screening committee for Southern California Biomedical Council’s Annual Investor Conference.
JERRY JOSEPH | RETIRED BUSINESS EXECUTIVE
Jerry Joseph, Experienced in marketing research, forecasting and business/strategic planning roles in the pharmaceutical, biotechnology, medical device and in vitro diagnostics categories. Established global strategy to commercialize Allergan’s then-emerging Botox® business. Developed Allergan’s initial corporate strategic plan after having spun off from SmithKline-Beckman as an independent, NYSE-traded company. Conducted global pre-launch research on Restasis® and other major new products.
JERRY E. KNOTTS | PRESIDENTS | CALIFORNIA COAST VENTURE FORUM
Jerry Knotts is a serial entrepreneur and has worked with entrepreneurs for over 20 years. Over this period of time, he created four companies and mentored over 250 start-ups.
Currently, Jerry is President, California Coast Venture Forum, Inc. and Entrepreneurs Without Borders, both based in Santa Barbara, and serves as mentor and screener for the Southern California BioMedical Council (SoCALBIO).
He is a member of the CLU School of Management, Dean’s Board of Advisors. President, Youth Enrichment Foundation, and Treasurer Air Warrior Courage Foundation.
He has been Vice-President/General Manager, Defense Electronics Division, California Microwave and Vice-President for Programs & Business Development at American Nucleonics Corporation. Jerry holds a BSEE (Electronics Engineering) from The Pennsylvania State University; and an MBA from Auburn University. Jerry is a licensed, Registered Professional Engineer.
DOUGLAS C. LANE | BUSINESS EXECUTIVE
Douglas Lane is a business executive with international experience in biotech and tech companies including London-based SmithKline Beecham Corporation, now GlaxoSmithKline, where he conducted M&A and joint ventures, was the business development appointee to SKB’s seminal joint venture with Human Genome Sciences, Inc., and served on HGSI’s Board of Directors. He’s held biotech and tech company senior executive, Chairman and CEO positions in several companies including a successful IPO. He currently helps biotech and early-stage businesses through his firm, Douglas C Lane Advisors, and serves as an instructor at California State University Channel Islands and Dominican University in San Rafael, CA teaching MBA and graduate biotech courses. He holds bachelor degrees in Psychology and a dual degree in Microbiology and Biochemistry, and an MBA in Finance. He attended the University of Southern California on an athletic scholarship, was twice All-American in track and field, and won a NCAA championship in the shot put event. He credits much of his success to the discipline and focus developed in his athletic and corporate training.
THOMAS LOBL | ENTREPRENEUR IN RESIDENCE | AMI-USC
Thomas Lobl, Ph.D. Entrepreneur in Residence (EIR), AMI-USC; Consultant
Tom works with the new project development group at AMI to help identify USC and other technologies which have commercially important potential in biomedical areas. He works with the AMI team to assess the medical/scientific potential of technologies and to help move forward the technology until it is ready to license to a for-profit company or spin out into a start-up company.
Tom has over 45 years of experience in the pharmaceutical and medical device industries and been involved at the bench and management levels in nearly every aspect of pharmaceutical discovery, research and development from idea generation through clinical trials.